Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
First Claim
1. A method for producing activated antigen-specific CD8+ cytotoxic T cells that selectively recognize cancer cells that aberrantly present a peptide consisting of the amino acid sequence of VVYDDSTGLIRL (SEQ ID NO:
- 81) in a complex with an HLA-A*02 comprising;
isolating CD8+ T cells from a HLA-A*02 donor;
contacting the isolated CD8+ T cells with antigen-presenting cells that display an antigen in a complex with HLA-A*02 for a period of time sufficient to activate the CD8+T cells, wherein said antigen is a peptide consisting of the amino acid sequence of VVYDDSTGLIRL (SEQ ID NO;
81).
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Citations
11 Claims
-
1. A method for producing activated antigen-specific CD8+ cytotoxic T cells that selectively recognize cancer cells that aberrantly present a peptide consisting of the amino acid sequence of VVYDDSTGLIRL (SEQ ID NO:
- 81) in a complex with an HLA-A*02 comprising;
isolating CD8+ T cells from a HLA-A*02 donor; contacting the isolated CD8+ T cells with antigen-presenting cells that display an antigen in a complex with HLA-A*02 for a period of time sufficient to activate the CD8+T cells, wherein said antigen is a peptide consisting of the amino acid sequence of VVYDDSTGLIRL (SEQ ID NO;
81). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
- 81) in a complex with an HLA-A*02 comprising;
Specification